SEC Filings

10-Q
ENVISION HEALTHCARE CORP filed this Form 10-Q on 11/03/2017
Entire Document
 
Item 1. Financial Statements - (continued)

Envision Healthcare Corporation
Consolidated Statements of Cash Flows (unaudited)
(In millions)
 
Nine Months Ended September 30,
 
2017
 
2016
Cash flows from operating activities:
 

 
 
Net earnings (loss)
$
(204.2
)
 
$
283.4

Adjustments to reconcile net earnings (loss) to net cash flows provided by operating activities:
 
 
 
Depreciation and amortization
324.4

 
90.7

Amortization of deferred loan costs
12.8

 
6.4

Provision for uncollectibles
3,813.1

 
359.3

Net (gain) loss on disposals and deconsolidations
8.8

 
(6.7
)
Share-based compensation
40.4

 
21.2

Deferred income taxes
574.7

 
34.6

Equity in earnings of unconsolidated affiliates
(16.0
)
 
(18.4
)
Impairment charges
0.3

 

Net change in fair value of contingent consideration
0.3

 
(2.6
)
Other, net

 
(3.9
)
Increases (decreases) in cash and cash equivalents, net of acquisitions and dispositions:
 
 
 
Accounts receivable
(4,011.7
)
 
(387.7
)
Supplies inventory
(0.3
)
 
(0.7
)
Prepaid and other current assets
(0.6
)
 
(16.1
)
Accounts payable
(7.0
)
 
(5.6
)
Accrued expenses and other liabilities
15.0

 
(14.4
)
Other, net
11.0

 
11.5

Net cash flows provided by operating activities
561.0

 
351.0

Cash flows from investing activities:
 
 
 
Acquisitions and related expenses, net of cash acquired
(694.4
)
 
(351.7
)
Acquisition of property and equipment
(138.5
)
 
(64.0
)
Increase in cash due to consolidation of previously unconsolidated affiliates

 
31.4

Purchases of marketable securities
(18.7
)
 
(0.5
)
Maturities of marketable securities
7.2

 
3.0

Other, net
(4.2
)
 
(6.5
)
Net cash flows used in investing activities
(848.6
)
 
(388.3
)
Cash flows from financing activities:
 
 
 
Proceeds from long-term borrowings
801.2

 
430.0

Repayment on long-term borrowings
(328.0
)
 
(214.3
)
Distributions to noncontrolling interests
(174.3
)
 
(172.1
)
Proceeds from issuance of common stock upon exercise of stock options
4.0

 
0.5

Repurchase of common stock
(9.4
)
 
(6.1
)
Financing costs incurred
(3.5
)
 

Other, net
(14.7
)
 
(1.3
)
Net cash flows provided by financing activities
275.3

 
36.7

Net decrease in cash and cash equivalents
(12.3
)
 
(0.6
)
Cash and cash equivalents, beginning of period
331.6

 
106.7

Less cash and cash equivalents of held for sale assets, end of period
41.2

 

Cash and cash equivalents, end of period
$
278.1

 
$
106.1


See accompanying notes to the unaudited consolidated financial statements.
5